Pretreatment Circulating Albumin, Platelet, and RDW-SD Associated with Worse Disease-Free Survival in Patients with Breast Cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Yao MM, Vpt V, Chen TH, et al. Performance measures of 8,169,869 examinations in the National Breast Cancer Screening Program in Taiwan, 2004–2020. BMC Med. 2023;21(1):497. doi:10.1186/s12916-023-03217-7
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. SEER Stat Fact Sheets: breast cancer. Available from: http://seer.cancer.gov/statfacts/html/breast.html. Accessed September 9, 2013.
   Google Scholar
• Cheng L, Swartz MD, Zhao H, et al. Hazard of recurrence among women after primary breast cancer treatment-a 10-year follow-up using data from SEER-Medicare. Cancer Epidemiol Biomarkers Prev. 2012;21(5):800–809. doi:10.1158/1055-9965.EPI-11-1089
   PubMed Web of Science ®Google Scholar
• Wang Y, Gavan SP, Steinke D, Cheung KL, Chen LC. The impact of age on health utility values for older women with early-stage breast cancer: a systematic review and meta-regression. Health Qual Life Outcomes. 2022;20(1):169. doi:10.1186/s12955-022-02067-w
   PubMed Web of Science ®Google Scholar
• Subramaniyan V, Fuloria S, Gupta G, et al. A review on epidermal growth factor receptor’s role in breast and non-small cell lung cancer. Chem Biol Interact. 2022;351:109735. doi:10.1016/j.cbi.2021.109735
   PubMed Web of Science ®Google Scholar
• Thapa R, Afzal O, Gupta G, et al. Unveiling the connection: long-chain non-coding RNAs and critical signaling pathways in breast cancer. Pathol Res Pract. 2023;249:154736. doi:10.1016/j.prp.2023.154736
   PubMed Web of Science ®Google Scholar
• Hirko KA, Rocque G, Reasor E, et al. The impact of race and ethnicity in breast cancer-disparities and implications for precision oncology. BMC Med. 2022;20(1):72. doi:10.1186/s12916-022-02260-0
   PubMed Web of Science ®Google Scholar
• Yersal O, Barutca S. Biological subtypes of breast cancer: prognostic and therapeutic implications. World J Clin Oncol. 2014;5(3):412–424. doi:10.5306/wjco.v5.i3.412
   PubMedGoogle Scholar
• Brandt J, Garne JP, Tengrup I, Manjer J. Age at diagnosis in relation to survival following breast cancer: a cohort study. World J Surg Oncol. 2015;13(1):33. doi:10.1186/s12957-014-0429-x
   PubMedGoogle Scholar
• Li J, Xia Y, Wu Q, et al. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: a population-based study from the SEER program. Oncotarget. 2017;8(30):49370–49379. doi:10.18632/oncotarget.17217
   PubMedGoogle Scholar
• Liu J, Li Y, Zhang W, et al. The prognostic role of lymph node ratio in breast cancer patients received neoadjuvant chemotherapy: a dose-response meta-analysis. Front Surg. 2022;9:971030. doi:10.3389/fsurg.2022.971030
   PubMedGoogle Scholar
• Fisher B, Slack NH, Bross ID. Cancer of the breast: size of neoplasm and prognosis. Cancer. 1969;24(5):1071–1080. doi:10.1002/1097-0142(196911)24:5<1071::AID-CNCR2820240533>3.0.CO;2-H
   PubMed Web of Science ®Google Scholar
• Bae SY, Kim S, Lee JH, et al. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer. BMC Cancer. 2015;15(1):138. doi:10.1186/s12885-015-1121-4
   PubMedGoogle Scholar
• Bundred JR, Michael S, Stuart B, et al. Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis. BMJ. 2022;378:e070346. doi:10.1136/bmj-2022-070346
   PubMedGoogle Scholar
• Ma X, Chen J, Ma D, et al. Delayed initiation of radiation therapy is associated with inferior outcomes for breast cancer patients with hormone receptor-negative tumors after breast-conserving surgery. Gland Surg. 2021;10(9):2631–2643. doi:10.21037/gs-20-717
   PubMed Web of Science ®Google Scholar
• Collin LJ, Cronin-Fenton DP, Ahern TP, et al. Early discontinuation of endocrine therapy and recurrence of breast cancer among premenopausal women. Clin Cancer Res. 2021;27(5):1421–1428. doi:10.1158/1078-0432.CCR-20-3974
   PubMed Web of Science ®Google Scholar
• Hung WC, Tang WH, Yu TH, et al. Low plasma growth/differentiation factor 1 levels are associated with liver fibrosis in patients with stable angina. J Clin Lab Anal. 2022;36(11):e24745. doi:10.1002/jcla.24745
   PubMed Web of Science ®Google Scholar
• Wei CT, Tsai IT, Wu CC, et al. Elevated plasma level of neutrophil gelatinase- associated lipocalin (NGAL) in patients with breast cancer. Int J Med Sci. 2021;18(12):2689–2696. doi:10.7150/ijms.58789
   PubMed Web of Science ®Google Scholar
• Kong X, Ma Y, Chen J, et al. Evaluation of the chronic kidney disease epidemiology collaboration equation for estimating glomerular filtration rate in the Chinese population. Nephrol Dial Transplant. 2013;28(3):641–651. doi:10.1093/ndt/gfs491
   PubMed Web of Science ®Google Scholar
• Arriagada R, Rutqvist LE, Kramar A, Johansson H. Competing risks determining event-free survival in early breast cancer. Br J Cancer. 1992;66(5):951–957. doi:10.1038/bjc.1992.391
   PubMed Web of Science ®Google Scholar
• O’Sullivan CC, Bradbury I, Campbell C, et al. Efficacy of adjuvant trastuzumab for patients with human epidermal growth factor receptor 2-positive early breast cancer and tumors ≤ 2 cm: a meta-analysis of the randomized trastuzumab trials. J Clin Oncol. 2015;33(24):2600–2608. doi:10.1200/JCO.2015.60.8620
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection. Evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285(19):2486–2497. doi:10.1001/jama.285.19.2486
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35(Supplement_1):S64–S71. doi:10.2337/dc12-s064
   PubMed Web of Science ®Google Scholar
• Byrne BM. Structural Equation Modeling with AMOS: Basic Concepts, Applications, and Programming. 2nd ed. New York: Routledge; 2009.
   Google Scholar
• Hsiao PC, Liu JT, Lin CL, Chou W, Lu SR. Risk of breast cancer recurrence in patients receiving manual lymphatic drainage: a hospital-based cohort study. Ther Clin Risk Manag. 2015;11:349–358. doi:10.2147/TCRM.S79118
   PubMed Web of Science ®Google Scholar
• Hoogenboezem EN, Duvall CL. Harnessing albumin as a carrier for cancer therapies. Adv Drug Deliv Rev. 2018;130:73–89. doi:10.1016/j.addr.2018.07.011
   PubMed Web of Science ®Google Scholar
• Sarett SM, Werfel TA, Lee L, et al. Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing. Proc Natl Acad Sci U S A. 2017;114(32):E6490–E6497. doi:10.1073/pnas.1621240114
   PubMed Web of Science ®Google Scholar
• Laursen I, Briand P, Lykkesfeldt AE. Serum albumin as a modulator on growth of the human breast cancer cell line, MCF-7. Anticancer Res. 1990;10(2A):343–351.
   PubMed Web of Science ®Google Scholar
• Lis CG, Grutsch JF, Vashi PG, Lammersfeld CA. Is serum albumin an independent predictor of survival in patients with breast cancer? JPEN J Parenter Enteral Nutr. 2003;27(1):10–15. doi:10.1177/014860710302700110
   PubMed Web of Science ®Google Scholar
• Sonmez O, Sonmez M. Role of platelets in immune system and inflammation. Porto Biomed J. 2017;2(6):311–314. doi:10.1016/j.pbj.2017.05.005
   PubMedGoogle Scholar
• Agarwal S. Red cell distribution width, inflammatory markers and cardiorespiratory fitness: results from the national health and nutrition examination survey. Indian Heart J. 2012;64(4):380–387. doi:10.1016/j.ihj.2012.06.006
   PubMedGoogle Scholar
• Free SR, Carraway KL. Platelets in hematogenous breast cancer metastasis: partners in crime. In: Mayrovitz HN, editor. Breast Cancer. Brisbane (AU): Exon Publications; 2022.
   Google Scholar
• Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9(2):237–249. doi:10.1111/j.1538-7836.2010.04131.x
   PubMed Web of Science ®Google Scholar
• Demirkol S, Balta S, Cakar M, Unlu M, Arslan Z, Kucuk U. Red cell distribution width: a novel inflammatory marker in clinical practice. Cardiol J. 2013;20(2):209. doi:10.5603/CJ.2013.0037
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Semba RD, Patel KV, Ferrucci L, et al. Serum antioxidants and inflammation predict red cell distribution width in older women: the women’s health and aging study I. Clin Nutr. 2010;29(5):600–604. doi:10.1016/j.clnu.2010.03.001
   PubMed Web of Science ®Google Scholar
• Yin JM, Zhu KP, Guo ZW, Yi W, He Y, Du GC. Is red cell distribution width a prognostic factor in patients with breast cancer? A meta-analysis. Front Surg. 2023;10:1000522. doi:10.3389/fsurg.2023.1000522
   PubMed Web of Science ®Google Scholar
• Liu S, Fang J, Jiao D, Liu Z. Elevated platelet count predicts poor prognosis in breast cancer patients with supraclavicular lymph node metastasis. Cancer Manag Res. 2020;12:6069–6075. doi:10.2147/CMAR.S257727
   PubMed Web of Science ®Google Scholar
• Zhang X, Wu Q, Hu T, Gu C, Bi L, Wang Z. Elevated red blood cell distribution width contributes to poor prognosis in patients undergoing resection for nonmetastatic rectal cancer. Medicine. 2018;97(3):e9641. doi:10.1097/MD.0000000000009641
   PubMed Web of Science ®Google Scholar
• Weng M, Zhao W, Yue Y, et al. High preoperative white blood cell count determines poor prognosis and is associated with an immunosuppressive microenvironment in colorectal cancer. Front Oncol. 2022;12:943423. doi:10.3389/fonc.2022.943423
   PubMed Web of Science ®Google Scholar
• Pierce JP, Patterson RE, Senger CM, et al. Lifetime cigarette smoking and breast cancer prognosis in the after breast cancer pooling project. J Natl Cancer Inst. 2014;106(1):djt359. doi:10.1093/jnci/djt359
   PubMedGoogle Scholar
• Steinberg J, Erlichman C, Gadalla T, Fine S, Wong A. Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. Eur J Cancer. 1992;28A(11):1817–1820. doi:10.1016/0959-8049(92)90011-P
   PubMed Web of Science ®Google Scholar
• Gitlin N. Salicylate hepatotoxicity: the potential role of hypoalbuminemia. J Clin Gastroenterol. 1980;2(3):281–285. doi:10.1097/00004836-198009000-00018
   PubMed Web of Science ®Google Scholar
• Giannakeas V, Kotsopoulos J, Brooks JD, et al. Platelet count and survival after cancer. Cancers. 2022;14(3):549. doi:10.3390/cancers14030549
   PubMed Web of Science ®Google Scholar
• Shirai Y, Shiba H, Haruki K, et al. Preoperative platelet-to-albumin ratio predicts prognosis of patients with pancreatic ductal adenocarcinoma after pancreatic resection. Anticancer Res. 2017;37:787–793. doi:10.21873/anticanres.11378
   PubMed Web of Science ®Google Scholar
• Don BR, Kaysen G. Serum albumin: relationship to inflammation and nutrition. Semin Dial. 2004;17(6):432–437. doi:10.1111/j.0894-0959.2004.17603.x
   PubMed Web of Science ®Google Scholar
• Kurtoğlu E, Aktürk E, Korkmaz H, et al. Elevated red blood cell distribution width in healthy smokers. Turk Kardiyol Dern Ars. 2013;41:199–206.
   PubMedGoogle Scholar
• Gradishar WJ, Moran MS, Abraham J, et al. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(6):691–722. doi:10.6004/jnccn.2022.0030
   PubMed Web of Science ®Google Scholar
• Zhang W, Xu Y, Wang Y, et al. Prognostic analysis of three forms of Ki-67 in patients with breast cancer with non-pathological complete response before and after neoadjuvant systemic treatment. Cancer Med. 2023;12(8):9363–9372. doi:10.1002/cam4.5693
   PubMed Web of Science ®Google Scholar
• Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62(1):233–247. doi:10.1146/annurev-med-070909-182917
   PubMedGoogle Scholar
• Chang M. Tamoxifen resistance in breast cancer. Biomol Ther. 2012;20(3):256–267. doi:10.4062/biomolther.2012.20.3.256
   PubMed Web of Science ®Google Scholar
• Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9(9):631–643. doi:10.1038/nrc2713
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Kim J, Haque R. Adherence to endocrine therapy in breast cancer adjuvant and prevention settings. Cancer Prev Res. 2014;7(4):378–387. doi:10.1158/1940-6207.CAPR-13-0389
   PubMed Web of Science ®Google Scholar
• Malavasi E, Giamas G, Gagliano T. Estrogen receptor status heterogeneity in breast cancer tumor: role in response to endocrine treatment. Cancer Gene Ther. 2023;30(7):932–935. doi:10.1038/s41417-023-00618-x
   PubMed Web of Science ®Google Scholar
• Johnsson A, Fugl-Meyer K, Bordas P, Åhman J, Von Wachenfeldt A. Side effects and its management in adjuvant endocrine therapy for breast cancer: a matter of communication and counseling. Breast Cancer. 2023;17:11782234221145440. doi:10.1177/11782234221145440
   Web of Science ®Google Scholar
• Asghari A, Wall K, Gill M, et al. A novel group of genes that cause endocrine resistance in breast cancer identified by dynamic gene expression analysis. Oncotarget. 2022;13(1):600–613. doi:10.18632/oncotarget.28225
   PubMedGoogle Scholar
• West HJ, Jin JO. JAMA oncology patient page. performance status in patients with cancer. JAMA Oncol. 2015;1(7):998. doi:10.1001/jamaoncol.2015.3113
   PubMed Web of Science ®Google Scholar
• Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27–41. doi:10.1016/j.immuni.2019.06.025
   PubMed Web of Science ®Google Scholar
• Patysheva M, Larionova I, Stakheyeva M, et al. Effect of early-stage human breast carcinoma on monocyte programming. Front Oncol. 2022;11:800235. doi:10.3389/fonc.2021.800235
   PubMed Web of Science ®Google Scholar
• Marone G, Schroeder JT, Mattei F, et al. Is there a role for basophils in cancer? Front Immunol. 2020;11:2103. doi:10.3389/fimmu.2020.02103
   PubMed Web of Science ®Google Scholar
• Park B, Lee HS, Lee JW, Park S. Association of white blood cell count with breast cancer burden varies according to menopausal status, body mass index, and hormone receptor status: a case-control study. Sci Rep. 2019;9(1):5762. doi:10.1038/s41598-019-42234-6
   PubMedGoogle Scholar
• Lamy PJ, Durigova A, Jacot W. Iron homeostasis and anemia markers in early breast cancer. Clin Chim Acta. 2014;434:34–40. doi:10.1016/j.cca.2014.04.011
   PubMed Web of Science ®Google Scholar
• Kumie G, Melak T, Wondifraw Baynes H. The Association of serum lipid levels with breast cancer risks among women with breast cancer at felege hiwot comprehensive specialized hospital, Northwest Ethiopia. Breast Cancer. 2020;12:279–287. doi:10.2147/BCTT.S279291
   PubMed Web of Science ®Google Scholar
• Abdelsalam KE, Hassan IK, Sadig IA. The role of developing breast cancer in alteration of serum lipid profile. J Res Med Sci. 2012;17(6):562–565.
   PubMed Web of Science ®Google Scholar
• Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010;9(1):69. doi:10.1186/1475-2891-9-69
   PubMed Web of Science ®Google Scholar
• Lee J, Kim SH, Kang BJ. Prognostic factors of disease recurrence in breast cancer using quantitative and qualitative Magnetic Resonance Imaging (MRI) parameters. Sci Rep. 2020;10(1):7598. doi:10.1038/s41598-020-64564-6
   PubMed Web of Science ®Google Scholar
• Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397(10286):1750–1769. doi:10.1016/S0140-6736(20)32381-3
   PubMed Web of Science ®Google Scholar
• Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11(2):174–183. doi:10.1016/S1470-2045(09)70262-1
   PubMed Web of Science ®Google Scholar
• Zhu X, Chen L, Huang B, et al. The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. Sci Rep. 2020;10(1):225. doi:10.1038/s41598-019-57094-3
   PubMed Web of Science ®Google Scholar
• Fuso P, Muratore M, D’Angelo T, et al. PI3K inhibitors in advanced breast cancer: the past, the present, new challenges and future perspectives. Cancers. 2022;14(9):2161. doi:10.3390/cancers14092161
   PubMed Web of Science ®Google Scholar
• Turner S, Chia S, Kanakamedala H, et al. Effectiveness of alpelisib + fulvestrant compared with real-world standard treatment among patients with HR+, HER2–, PIK3CA -mutated breast cancer. Oncologist. 2021;26(7):1133–e1142. doi:10.1002/onco.13804
   Web of Science ®Google Scholar
• Rizwi FA, Abubakar M, Puppala ER, et al. Janus kinase-signal transducer and activator of transcription inhibitors for the treatment and management of cancer. J Environ Pathol Toxicol Oncol. 2023;42(4):15–29. doi:10.1615/JEnvironPatholToxicolOncol.2023045403
   PubMed Web of Science ®Google Scholar
• Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023;22(2):101–126. doi:10.1038/s41573-022-00579-0
   PubMed Web of Science ®Google Scholar
• Sussell JA, Press DJ, Hansen SA, Kim E, Du Toit Y, Fung A. Impact of pertuzumab and ado-trastuzumab emtansine on cumulative avoidance of recurrence among women treated for locally advanced, inflammatory, or early-stage nonmetastatic HER2-positive breast cancer in the United States. Adv Ther. 2023;40(9):3857–3874. doi:10.1007/s12325-023-02554-6
   PubMed Web of Science ®Google Scholar
• André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-Mutated, hormone receptor-Positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–1940. doi:10.1056/NEJMoa1813904
   PubMed Web of Science ®Google Scholar
• Cortés J, Kim SB, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143–1154. doi:10.1056/NEJMoa2115022
   PubMed Web of Science ®Google Scholar